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1. Introduction  
Psychological interventions are now well established as a core part of modern pain 
practice.  Randomized controlled trials (RCT) of psychological treatment for chronic pain 
first appeared in the 1970s and considerable effort, skill, and sophistication have been 
applied to establishing the evidence of effectiveness [26]. Over the last two decades  we and 
others have conducted systematic reviews and meta-analyses of psychological interventions, 
predominantly cognitive behavior therapy (CBT), for chronic pain [3; 6; 8; 16; 17; 27; 40].  
Meta-analysis facilitates the emergence of underlying patterns in data by controlling the bias 
and error inherent in individual studies. These meta-analyses suggest that, overall, CBT has 
a beneficial average effect for a range of outcomes, principally disability, depression, and 
pain experience.  Evidence of harms is not available.  Although the headline effect is 
positive, current analyses are limited to average results and conclusions are typically 
confined to the general.  
The aim of this topical review is to consider the next steps in developing and 
evaluating psychological treatments for chronic pain.  In this examination we take as our 
‘unit-of analysis’ the meta-analyses rather than individual RCTs.  We briefly summarize the 
results of the meta-analyses, their benefits and limits and then offer directions for improving 
the next generation of studies.  We argue that we have reached a critical point in the 
evolution of psychological interventions and a paradigm shift is now needed in how we 
investigate treatment efficacy, effectiveness, and harm. 
2. Evidence from meta-analysis 
Our first meta-analysis [27], showed CBT to be more effective (comparing groups 
post-treatment) than no-treatment/treatment as usual (TAU) for outcomes of pain, pain 
experience, cognitive coping and appraisal, behavioral expression of pain, mood/affect, and 
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social role functioning, with a median effect size ES(d) of 0.5.  There was marginal evidence 
that CBT was superior to other active treatments.  In later analyses, using improved 
methods, CBT remained superior to no-treatment/TAU, but the magnitude of d diminished 
to around 0.2 [8; 40]; similar to effect sizes in other meta-analyses for mixed chronic pain [33] 
low back pain [16; 17], fibromyalgia [3; 11; 14], and arthritis [6].  The smaller recent effect 
sizes  are likely due to improvements in the control of bias such as a stricter criterion for 
entry on individual study sample size [30].  The methodological quality in the design of 
trials, including risk of bias, improved over time, but treatment quality did not (see figure 2 
in [26]).  This held after excluding many trials for inadequate/insufficient psychotherapeutic 
content.  Despite having more and better designed trials for meta-analysis, the picture 
remains unclear.  Half of the comparisons showed no effect of CBT and half showed weak 
effect sizes of unknown clinical significance on pain, mood, disability and catastrophic 
thinking outcomes [40].  The clarity of any overall effect is muddied by three main sources: 
(i) sample, measure, and treatment heterogeneity; (ii) unexplained variation of outcome 
reporting across studies; and (iii) theoretical imprecision.  
In summary, current meta-analyses indicate that psychological treatments are likely 
to be effective. However, as more studies are produced and added to meta-analyses, the 
results are effectively being diluted by the addition of poorly conceived, conducted, and 
reported trials.  The signal to noise ratio is shrinking.  Meta-analysis cannot control for poor 
primary studies or poor reporting [20].  Additional trials that are atheoretical, biased, single 
center, and enthusiasm-driven will make summary and interpretation increasingly difficult.  
We suggest that, without radical change, simply adding further trials will not help us to 
improve treatment effectiveness nor help answer research questions.  
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This is not a counsel of despair.  We are not arguing for the abandonment of the 
program of developing and testing psychological treatments for chronic pain.  This would 
be a misreading: psychological therapies for the management of chronic pain offer 
worthwhile and promising treatments.  We seek rather to build on the evidence base, but 
suggest changing our methods of investigation [22; 32].  If we do not improve the methods 
of primary investigation and learn from the trial developments in other areas of pain 
investigation then we will achieve only confusion [32]. 
3. The complexity of chronic pain 
Chronic pain is complexly maintained and its treatment resistance should not 
surprise us.  In fact recently it has been argued that analgesic failure is to be expected and 
should be a guiding treatment principle of all chronic pain treatment [21].  Patients present 
with disability established over many years.  Many of the trials present treatments of brief 
duration, sometimes delivered by personnel trained just for that trial: good clinical outcomes 
are rather less likely from dilute/short treatments delivered by inexperienced staff to 
severely distressed patients.  Perhaps we have underestimated the complexity of behavior 
change and the social and psychological influences that maintain disability in chronic pain 
patients [4].  Even if pain can be modulated by non-psychological methods, the complexity 
of psychological and behavioral adaptation means that the interruptive, interfering and 
identity-distorting impacts of pain are no longer functionally related to the immediate 
experience of pain but are controlled by contextual behavioral, social and cognitive factors 
that require therapeutic attention [10; 18; 23].  
4.  Heterogeneity in patient populations and treatment complexity 
Many trials have mixed patient samples made up of patients with many and varied 
diagnoses.  Critics have argued for greater specificity and trials are emerging of single-
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diagnosis patient samples.  Identifying groups of patients by disease or disorder may aid 
evidence-based translation to clinical practice, but psychological profiles are often 
orthogonal to medical diagnosis [9].  Diagnostic group membership is largely unhelpful in 
explaining patient pain behavior or in guiding treatment decisions.  Entry criteria for trials 
rarely specify levels of distress or disability other than to exclude participants with 
intellectual limitations, overt symptoms of psychosis or addiction.  The distribution of scores 
on measures of depression and distress covers the full spectrum.  A psychologically-
informed characterization of patients might facilitate better targeted and more effective 
treatment but the optimal method for patient group determination is still under debate [29; 
36; 38].  Many of the trials entered into meta-analyses comprise pragmatic mixes of 
treatment content.  The rationale for treatment choice and blend in multicomponent 
treatments is often unreported, and perhaps of more concern, there is often a disparity 
between the aims of treatment, the actual treatment content, and outcomes reported.  This 
makes it difficult to discern which components of treatment contribute to specific changes.  
Component dismantling studies offer an illusion of identifying ‘active ingredients’ but 
cannot achieve sufficient power to calculate the effects of each component on each outcome 
[12].  It is worth noting that within the general field of psychotherapy it is difficult to obtain 
effect sizes significantly different from zero for the difference between treatment packages 
with and without a putatively effective component [1]. 
5. Outcome measures and measurement 
Historically, psychological treatments have utilized outcomes with continuous 
measures that are expressed by Cohen’s ES(d) and its variants.  This has inherent practical 
limitations and implications.  The between-group ES of 0.2, typical of recent meta-analyses, 
is unhelpful in communication with patients who want to know ‘what are my chances of 
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getting better?’  Replying that ‘the average person in the treated group is at the 58th 
percentile (or 69th percentile when (d) = 0.5) of the untreated group’, although accurate is 
unhelpful [24].  Most trials report statistical rather than clinical significance.  Rarely do trials 
report binary outcomes based on clinical significance criteria [24; 29].  Consequently we have 
no basis on which to estimate the number of successfully treated people.  Pre-post treatment 
effect sizes are also modest (~ 0.4) and do not approach the value of around 1.5 desired by 
patients [31; 34].  Finally, although diverse measures are reported in trials, it is not clear that 
they necessarily coincide with the interests of patients [2; 35]. Nor are adverse effects or 
dropout rates adequately recorded [28].  This may reflect inadequate preparation for 
treatment, or worse a failure of equipoise in which investigators simply do not expect 
failure.  
6. The next steps 
The treatment of chronic pain remains a challenge whether the primary aim is 
analgesic or rehabilitative.  The success rates (and effect sizes) for psychological treatments 
are similar to those reported for pharmacological and surgical interventions [5; 15].  What is 
different from the evidence base for non-psychological interventions is that as more trials of 
psychological treatments are published clarity becomes more not less elusive.  Additional 
low-quality trials of minor variations in therapy will not solve the problems outlined here 
and will only add noise.  A paradigm shift is necessary and long overdue. Three major 
advances are needed and we invite consideration and debate. 
First, we encourage the design of theoretically coherent evaluations and trials.  
Precise testable models are needed that link specific treatment procedures with specific 
psychological changes leading to hypothesized specific outcomes.  Therapy needs to be 
based on explicit theoretical models that guide choice of content, dose, timing and quality of 
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treatment, and the choice of specific outcomes.  There are examples of useful theory.  The 
evidence for graded exposure has been developed in a clinical context using single case 
methodology to systematically replicate and test its component processes [37].  The 
theoretically sophisticated functional affective-motivational model of attention and pain has 
been extensively explored and tested in laboratory settings [19].  It is markedly different 
from the limited channel capacity model upon which most clinical interventions for 
attention modulation are based [25] and is ripe for translation. 
Second, we propose a standardizing of key features of methodological quality and 
bias. In particular we should adopt the IMMPACT criteria on measurement domains and 
measurement tools [7].  We should judge small-n RCTs (including those labeled ‘feasibility’, 
‘preliminary’, and ‘exploratory’) as low quality[13] and encourage studies with adequate 
control over bias.  We need clear articulation of the severity of patient complaint using a 
shared language of the extent of disability, distress, and alterable behavior [39].  Critical to 
bias control will be an honest appraisal of the common lack of equipoise in psychological 
trials, and the requirement at the very least for the transparent reporting of therapist 
allegiance.  Finally, trials that do not measure or report adverse events should be considered  
fundamentally flawed.  
Third, alternatives to the randomized controlled trial should be considered.  
Rowbotham et al [32] recently argued that to properly address the clinical effectiveness of an 
efficacious treatment we need to invest in large scale observational and translational studies.  
This is relevant also in psychological interventions, and in particular for the benchmarking 
of achievable outcomes in regular clinical practice.  Single case methodologies are also 
infrequently used and have promise [37].  Advances in secondary data analysis are also 
relevant and analysis at the patient level across trials may be particularly relevant for 
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indirect comparisons between treatments. Responder analyses are also promising and 
should be explored.  Both will rely on open access to data. 
We argue that it is time for a radical change in how we design treatments, and study 
their effectiveness. A paradigm shift is essential.  We have gone as far as we can with the old 
models. The next generation of studies will need to raise the bar on quality. Studies that do 
not measure adverse events should be considered unethical. Studies that do not control 
therapist allegiance should be considered flawed. Studies that are small should be ignored.  
The next studies will better define homogenous samples of patients, and will match key 
sample features to treatment content and outcome assessment.  Access to data at an 
individual patient level will allow for responder analyses. And, access to larger datasets on 
community studies will allow for effectiveness studies at scale. Future systematic reviews 
will also lead improvement by being explicit and transparent about trial entry. Evidence will 
be graded with tools that recognize the influence of bias in individual trials, and innovative 
methods of portraying the results of comparative effectiveness studies to different 
stakeholders will improve their relevance. 
 
 
 
Conflict of interest 
The authors declare no conflict of interest 
  
9 
References 
 
[1] Ahn H, Wampold BE. Where oh where are the specific ingredients? A meta-analysis of 
component studies in counseling and psychotherapy. J Counsel Psychol 
2001;48(3):251-257. doi: 10.1037/0022-0167.48.3.251. 
[2] Beale M, Cella M, Williams ACd. Comparing patients' and clinician-researchers' outcome 
choice for psychological treatment of chronic pain. Pain 2011;152(10):2283-2286. doi: 
10.1016/j.pain.2011.06.007. 
[3] Bernardy K, Fuber N, Kollner V, Hauser W. Efficacy of cognitive-behavioral therapies in 
fibromyalgia syndrome - a systematic review and metaanalysis of randomized 
controlled trials. J Rheumatol 2010;37(10):1991-2005. doi: 10.3899/jrheum.100104. 
[4] Blyth FM, Macfarlane GJ, Nicholas MK. The contribution of psychosocial factors to the 
development of chronic pain: the key to better outcomes for patients? Pain 2007;129:8-
11. doi: doi:10.1016/j.pain.2007.03.009. 
[5] Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia 
in adults. Cochrane Database Syst Rev 2012;3:CD008244. doi: 
10.1002/14651858.CD008244.pub2. 
[6] Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP. Psychological interventions for 
arthritis pain management in adults: a meta-analysis. Health Psychol 2007;26(3):241-
250. doi: 10.1037/0278-6133.26.3.241. 
[7] Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, 
Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, 
Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott 
MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal 
10 
MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, Immpact. Core 
outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 
2005;113(1-2):9-19. doi: 10.1016/j.pain.2004.09.012. 
[8] Eccleston C, Williams AC, Morley S. Psychological therapies for the management of 
chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 
2009(2):CD007407. doi: 10.1002/14651858.CD007407.pub2. 
[9] Flor H, Turk DC. Chronic Pain: An Integrated Biobehavioral Approach. Seattle: IASP 
Press, 2011. 
[10] Fordyce WE. Behavioral methods for chronic pain and illness. St Louis: Mosby, 1976. 
[11] Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. 
Psychological treatments for fibromyalgia: a meta-analysis. Pain 2010;151(2):280-295. 
doi: 10.1016/j.pain.2010.06.011. 
[12] Grimshaw J, Freemantle N, Langhorne P, Song F. Complexity and systematic reviews: 
Report to the US Congress, Office of Technology Assessment.  1995:48. 
[13] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann 
HJ, Group GW. GRADE: an emerging consensus on rating quality of evidence and 
strength of recommendations. BMJ 2008;336(7650):924-926. doi: 
10.1136/bmj.39489.470347.AD. 
[14] Hauser W, Bernardy K, Arnold B, Offenbacher M, Schiltenwolf M. Efficacy of 
multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized 
controlled clinical trials. Arthritis Rheum 2009;61(2):216-224. doi: 10.1002/art.24276. 
[15] Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in 
adults. Cochrane Database of Systematic Reviews 2012;2:CD009318. doi: 
10.1002/14651858.CD009318.pub2. 
11 
[16] Henschke N, Ostelo RW, van Tulder MW, Vlaeyen JW, Morley S, Assendelft WJ, Main 
CJ. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev 
2009(7):CD002014. doi: 10.1002/14651858.CD002014.pub3. 
[17] Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological 
interventions for chronic low back pain. Health Psychol 2007;26(1):1-9. doi: 
10.1037/0278-6133.26.1.1. 
[18] Keefe FJ, Rumble ME, Scipio CD, Giordano LA, Perri LM. Psychological aspects of 
persistent pain: current state of the science. J Pain 2004;5(4):195-211. doi: 
10.1016/j.jpain.2004.02.576. 
[19] Legrain V, Damme SV, Eccleston C, Davis KD, Seminowicz DA, Crombez G. A 
neurocognitive model of attention to pain: behavioral and neuroimaging evidence. 
Pain 2009;144(3):230-232. doi: 10.1016/j.pain.2009.03.020. 
[20] Moore A, McQuay H. Bandolier's Little Book of Making Sense of the Medical Evidence. 
Oxford: Oxford University Press, 2006. 
[21] Moore RA, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic 
success. BMJ in press. 
[22] Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, Bell RF, Kalso E, 
Rowbotham MC, Actinpain writing group of the IASP Special Interest Group on 
Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial 
design more relevant to clinical practice, acknowledging the importance of individual 
differences. Pain 2010;149(2):173-176. doi: 10.1016/j.pain.2009.08.007. 
[23] Morley S. Psychology of pain. Br J Anaesth 2008;101(1):25-31. doi: 10.1093/bja/aen123. 
[24] Morley S. Trial design in psychological treatments: What can we tell patients? In: RA 
Moore, E Kalso, HJ McQuay, editors. Systematic reviews in and meta-analyses in pain: 
12 
Lessons from the past leading to pathways for the future. Seattle: IASP Press, 2008. pp. 
217-232. 
[25] Morley S. Attention management. In: R Bell, E Kalso, J Plaice, O Soyannwo, editors. A 
Global Problem: Cancer Pain from the Laboratory to the Bedside Seattle: IASP Press, 
2010. 
[26] Morley S. Efficacy and effectiveness of cognitive behaviour therapy for chronic pain: 
Progress and some challenges. Pain 2011;152(3):S99-S106. doi: 
10.1016/j.pain.2010.10.042. 
[27] Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized 
controlled trials of cognitive behaviour therapy and behaviour therapy for chronic 
pain in adults, excluding headache. Pain 1999;80(1-2):1-13. doi: 10.1016/S0304-
3959(98)00255-3. 
[28] Morley S, Williams A, Hussain S. Estimating the clinical effectiveness of cognitive 
behavioural therapy in the clinic: evaluation of a CBT informed pain management 
programme. Pain 2008;137(3):670-680. doi: 10.1016/j.pain.2008.02.025. 
[29] Morley S, Williams AC. RCTs of psychological treatments for chronic pain: progress and 
challenges. Pain 2006;121(3):171-172. doi: 10.1016/j.pain.2006.01.017. 
[30] Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M, Altman DG, Juni P. 
The effects of excluding patients from the analysis in randomised controlled trials: 
meta-epidemiological study. BMJ 2009;339( ):b3244. doi: 10.1136/bmj.b3244. 
[31] Robinson ME, Brown JL, George SZ, Edwards PS, Atchison JW, Hirsh AT, Waxenberg 
LB, Wittmer V, Fillingim RB. Multidimensional Success Criteria and Expectations for 
Treatment of Chronic Pain: The Patient Perspective. Pain Med 2005;6(5):336-345. doi: 
doi:10.1111/j.1526-4637.2005.00059.x. 
13 
[32] Rowbotham MC, Gilron I, Glazer C, Rice AS, Smith BH, Stewart WF, Wasan AD. Can 
Pragmatic Trials Help Us Better Understand Chronic Pain and Improve Treatment? 
Pain 2013;154:643-646. doi: 10.1016/j.pain.2013.02.034. 
[33] Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for 
chronic pain: a systematic review of interventions and outcomes. Rheumatology 
2008;47(5):670-678. doi: 10.1093/rheumatology/ken021. 
[34] Thorne FM, Morley S. Prospective judgments of acceptable outcomes for pain, 
interference and activity: Patient-determined outcome criteria. Pain 2009;144(3):262-
269. doi: 10.1016/j.pain.2009.04.004. 
[35] Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, Cleeland CS, Cowan 
P, Farrar JT, Hertz S, Max MB, Rappaport BA. Identifying important outcome domains 
for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain 
2008;137(2):276-285. doi: 10.1016/j.pain.2007.09.002. 
[36] Vlaeyen JWS, Morley S. Cognitive-Behavioral Treatments for Chronic Pain: What Works 
for Whom? Clin J Pain 2005;21(1):1-8. doi: 10.1097/00002508-200501000-00001. 
[37] Vlaeyen JWS, Morley S, Linton S, Boersma K, de Jong J. Pain-Related Fear: Exposure-
based Treatment of Chronic Pain. Seattle: IASP press, 2012. 
[38] Vlaeyen JWS, Morley SJ. Tailored treatment: It's not what you think it is. Comment on 
the article by van Koulil et al. Arth Care Res 2011;63(6):921-922. doi: 10.1002/acr.20455. 
[39] Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 
1992;50(2):133-149. doi: 10.1016/0304-3959(92)90154-4. 
[40] Williams AC, Eccleston C, Morley S. Psychological therapies for the management of 
chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 
2012;11:CD007407. doi: 10.1002/14651858.CD007407.pub3. 
